Complex phenotypic assays in high-throughput screening.
High-throughput screening (HTS), systematically testing thousands of small molecules to find candidates for lead optimization, primarily involves exposure of purified proteins to arrayed collections of small molecules. More complex phenotypic assays, such as cell-based or whole-organism assays, traditionally have flanked HTS, preceding it to validate new therapeutic targets, and following it to characterize new lead compounds in cellular contexts. Recently, however, cell- and organism-based phenotypic assays have increasingly been adopted as a primary screening platform for annotating small molecules.
Clemons
Paul A
PA
Initiative for Chemical Genetics, ICCB-Broad Institute, Harvard University, 320 Charles Street, Room 184, Cambridge, Massachusetts 02141, USA. pclemons@hms.harvard.edu
D020650:Combinatorial Chemistry Techniques / Q000379:methods*; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D005818:Genetic Engineering; D008490:Medical Informatics; D010363:Pattern Recognition, Automated; D010641:Phenotype; D013050:Spectrometry, Fluorescence